HOME >> BIOLOGY >> NEWS
Could USA presidential DNA trail reveal Middle-Eastern origins?

DNA testing carried out by University of Leicester geneticists and funded by The Wellcome Trust has thrown new light on the ancestry of one of the USAs most revered figures, the third President, Thomas Jefferson.

Almost 10 years ago, the University of Leicester team, led by Professor Mark Jobling, together with international collaborators, showed that Thomas Jefferson had fathered at least one of the sons of Sally Hemings, a slave of Jeffersons.

The work was done using the Y chromosome, a male-specific part of our DNA that passes down from father to son. Jefferson carried a very unusual Y chromosome type, which helped to strengthen the evidence in the historical paternity case.

Now, new techniques have been brought to bear on Jeffersons Y chromosome, in a study reported in the American Journal of Physical Anthropology. The presidential chromosome turns out to belong to a rare class called K2, which is found at its highest frequency in the Middle East and Eastern Africa, including Oman, Somalia and Iraq. Its closest match was in a man from Egypt. Could this mean that the President had recent ancestry in the Middle East? A careful survey revealed a few K2 chromosomes in France, Spain and England. Together, the K2s form a diverse group that may, in fact, have been in western Europe for many thousands of years.

Further evidence for Jeffersons British origins come from the finding that two out of 85 randomly recruited men named Jefferson share exactly the same Y chromosome as the President. Prof Jobling said: The two men have ancestry in Yorkshire and the West Midlands, and knew of no historical connection to the USA. They were amazed and fascinated by the link, which connects them into Thomas Jeffersons family tree, probably about 11 generations ago.

The ultimate origins of K2 chromosomes remain a mystery, however, and need further investigation: while they may have been present in Europe since the Stone Age, another
'"/>

Contact: Ather Mirza
pressoffice@le.ac.uk
01-162-522-415
University of Leicester
28-Mar-2007


Page: 1 2

Related biology news :

1. Could fungal collection hold the key to new life-saving drugs?
2. Could estriol be the elixir for MS?
3. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
4. Could a pint of cider help keep the doctor away?
5. Friend or foe: Could a protein linked to Alzheimers be related to vision loss in seniors?
6. Could plain soap and probiotics beat hospital bugs?
7. Could better mangrove habitats have spared lives in the 2004 tsunami?
8. Recurrent miscarriages: Could prednisolone reduce the occurrence of this distressing condition?
9. Could microbes solve Russias chemical weapons conundrum?
10. Could schizophrenia arise from a single defect?
11. Two Childrens Hospital Boston researchers win top presidential awards

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Could USA presidential DNA trail reveal Middle Eastern origins

(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: